Tandem Health raises $100M Series B led by EU's Scaleup Europe Fund

Swedish healthtech startup Tandem Health has raised $100 million in a Series B funding round led by the EU-backed €5 billion Scaleup Europe Fund, marking the fund's first investment in healthcare. Tandem Health, which provides an AI medical assistant used by 10,000 care organisations across 14 European markets, plans to use the capital to expand its European footprint and develop an AI-native clinic operating system. While a July 2026 study indicates significant administrative time savings for clinicians using the tool, AI scribes remain under scrutiny in the UK due to potential errors in NHS records.

Series B funding round

• ▪Tandem Health's $100 million Series B round follows a $50 million Series A in 2025, bringing the startup's total funding to $160 million.
• ▪The Scaleup Europe Fund, managed by EQT, led Tandem Health's Series B round, with participation from existing investors Kinnevik, Northzone, Amino Collective, and Visionaries.
• ▪Tandem Health did not disclose its valuation for the $100 million Series B funding round.
• ▪Stockholm-based healthtech startup Tandem Health raised $100 million in a Series B funding round announced on September 14, 2026.

AI medical assistant features

• ▪Tandem Health's AI medical assistant prepares patient summaries, offers clinical decision support, and handles documentation, coding, and follow-up tasks.
• ▪Tandem Health plans to develop an "AI-native Clinic Operating System" that adds triage, scheduling, and patient communications to its existing tools.
• ▪Three components of Tandem Health's product—the scribe, coding assistant, and decision support—gained Class IIa medical device certification under the EU Medical Device Regulation in mid-2026.

European market expansion

• ▪The United Kingdom is Tandem Health's largest market by the number of users.
• ▪Tandem Health's software is used by 10,000 care organisations across 14 European markets, including Ramsay Santé, Humanitas, and the National Health Service.
• ▪Tandem Health connects to more than 130 medical record systems across Europe.
• ▪In January 2026, Tandem Health acquired Juvoly, a Dutch AI scribe company that handled over 200,000 consultations monthly for more than 1,500 clinicians.

Clinical effectiveness research

• ▪Three of the six authors of the JMIR Medical Informatics study work at Tandem Health, including co-founder and CEO Lukas Saari.
• ▪A July 2026 study in JMIR Medical Informatics reported that clinicians using Tandem Health's software experienced 29% less administrative time, 30% higher job satisfaction, and 30% less stress.
• ▪In August 2026, reports emerged that AI scribes were entering incorrect drug names and diagnoses into United Kingdom National Health Service records.
• ▪The JMIR Medical Informatics study surveyed 177 clinicians at Capio Ramsay Santé in Sweden, who self-reported a documentation time reduction from 6.69 to 4.72 minutes.

Scaleup Europe Fund strategy

• ▪The Scaleup Europe Fund's investment in Tandem Health represents the fund's first investment in the healthcare and healthtech sector.
• ▪The Scaleup Europe Fund has backed other European technology startups, including Lovable's $400 million round in August 2026 and Mistral's €3 billion raise in September 2026.
• ▪The Scaleup Europe Fund is a €5 billion public-private fund set up by the European Commission to support and retain promising technology companies in Europe.
• ▪Founding investors in the Scaleup Europe Fund include the European Commission, Novo Holdings, CriteriaCaixa, and Santander.

Debatable claims

• ▪The EU should use public funds to back late-stage tech startups
• ▪The NHS should suspend the use of AI medical scribes